Presolicitation
Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
75A50126R00001_RFP_PreSolNotice_NPIVS-2027
Office of Assistant Secretary for Preparedness and Response, Barda - Aspr / Daappo / Barda DCMA. Research and Development in Biotechnology (except Nanobiotechnology).
Response deadline
August 15, 2026 at 5:00 PM EDT
Closed 78 days ago. Posted July 30, 2026. Scheduled to archive August 30, 2026.
Get the next one like this from Office of Assistant Secretary for Preparedness and Response by email, the day it is posted.Find my opportunities
This one closed in 2026
18 like it are open now in research and development in biotechnology (except nanobiotechnology)
- Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Office of Assistant Secretary for Preparedness and Response, Barda - Aspr / Daappo / Barda DCMA
SolicitationNAICS 541714Washington, DC75A50126R00001_RFP_NPIVS_27Closes in 19 daysNov 20 - ARPA-H Emerging Health Innovators (EHI) Initiative
National Institutes of Health, Advanced Research Projects Agency for Health (Arpa-H)
SolicitationNAICS 541714District of ColumbiaARPA-H-SOL-26-150Closes in 101 daysFeb 10, 2027 - BROAD AGENCY ANNOUNCEMENT - BIOMEDICAL RESEARCH AND DIVING EQUIPMENT DEVELOPMENT
Department of the Navy, NAVSEA HQ
SolicitationNAICS 541714District of ColumbiaN0002427S0001Closes in 394 daysNov 30, 2027
All 18 open in research and development in biotechnology (except nanobiotechnology)
Description
As published on SAM.gov.
Description:
BARDA seeks Contractor(s) to support the continuation of the Vaccine MCMs for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods.
Mandatory Qualification Requirements:
To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by:
- Holding a U.S. influenza vaccine license; or
- Have developed an influenza vaccine as evidenced by: a.Submission of a BLA for seasonal or pandemic influenza vaccine
Please see attachment to this presolicitation notice for further important information.
Attachments
Files listed on SAM.gov. The ones we hold a copy of download from here; the rest open SAM's download, which needs no account.
- 75A50126R00001 NPIVS RFP_PresolNotice.pdf160 KB, July 31, 2026
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
July 31, 2026
Presolicitation, originally sources sought
Due August 15, 2026 at 5:00 PM EDT. SAM.gov, notice 7f2d0909120749a39c61c64ff933f1a6
3 revisions on SAM
- July 31, 2026: publish, presolicitation
- August 17, 2026: publish, solicitation
- November 7, 2025: publish, sources sought
Points of contact
- Laura SaddisonLaura.Saddison@hhs.gov